Literature DB >> 19050968

Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer.

Chiung-Nien Chen1, Cheng-Chi Chang, Ting-En Su, Wen-Ming Hsu, Yung-Ming Jeng, Ming-Chih Ho, Fon-Jou Hsieh, Po-Huang Lee, Min-Liang Kuo, Hsinyu Lee, King-Jen Chang.   

Abstract

The purpose of this study was to identify genes of interest for a subsequent functional and clinical cohort study using complementary (c)DNA microarrays. cDNA microarray hybridization was performed to identify differentially expressed genes between tumor and nontumor specimens in 30 gastric cancer patients. Subsequent functional studies of the selected gene were carried out, including cell cycle analysis, cell migration analysis, analyses of vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF), and oligo-microarray studies using two pairs of stable cell lines of the selected gene. Another independent cohort study of 79 gastric cancer patients was conducted to evaluate the clinical significance of the selected gene in human gastric cancer. Calreticulin (CRT) was selected for further investigation. Two pairs of stable cell lines of CRT overexpression and CRT knockdown were constructed to perform functional studies. CRT enhanced gastric cancer cell proliferation and migration. Overexpressed CRT upregulated the expression and secretion of PlGF and VEGF. CRT had a reciprocal effect on connective tissue growth factor (CTGF) expression. Positive immunohistochemical staining of calreticulin was significantly correlated with high microvessel density (MVD) (p = 0.014), positive serosal invasion (p = 0.013), lymph node metastasis (p = 0.002), perineural invasion (p = 0.008), and poor patient survival (p = 0.0014). Multivariate survival analysis showed that CRT, MVD, and serosal invasion were independent prognosticators. We conclude that CRT overexpression enhances angiogenesis, and facilitates proliferation and migration of gastric cancer cells, which is in line with the association of CRT with MVD, tumor invasion, lymph node metastasis, and survival in gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050968     DOI: 10.1245/s10434-008-0243-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  49 in total

1.  Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Authors:  Mark P Chao; Siddhartha Jaiswal; Rachel Weissman-Tsukamoto; Ash A Alizadeh; Andrew J Gentles; Jens Volkmer; Kipp Weiskopf; Stephen B Willingham; Tal Raveh; Christopher Y Park; Ravindra Majeti; Irving L Weissman
Journal:  Sci Transl Med       Date:  2010-12-22       Impact factor: 17.956

2.  Connective tissue growth factor inhibits gastric cancer peritoneal metastasis by blocking integrin α3β1-dependent adhesion.

Authors:  Chiung-Nien Chen; Cheng-Chi Chang; Hong-Shiee Lai; Yung-Ming Jeng; Chia-I Chen; King-Jeng Chang; Po-Huang Lee; Hsinyu Lee
Journal:  Gastric Cancer       Date:  2014-07-02       Impact factor: 7.370

3.  Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression.

Authors:  Yi-Chien Lu; Chiung-Nien Chen; Bojeng Wang; Wen-Ming Hsu; Szu-Ta Chen; King-Jen Chang; Cheng-Chi Chang; Hsinyu Lee
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

Review 4.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

5.  Calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma.

Authors:  Koji Harada; Takanori Takenawa; Tarannum Ferdous; Yasuhiro Kuramitsu; Yoshiya Ueyama
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

6.  Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis.

Authors:  Daisuke Kobayashi; Shuji Nomoto; Yasuhiro Kodera; Michitaka Fujiwara; Masahiko Koike; Goro Nakayama; Norifumi Ohashi; Akimasa Nakao
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 7.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

8.  Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.

Authors:  Kristin Schneider; Astrid Weyerbrock; Soroush Doostkam; Karl Plate; Marcia Regina Machein
Journal:  J Neurooncol       Date:  2014-11-05       Impact factor: 4.130

9.  Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms.

Authors:  Tijana Subotički; Olivera Mitrović Ajtić; Bojana B Beleslin-Čokić; Ronny Nienhold; Miloš Diklić; Dragoslava Djikić; Danijela Leković; Tanja Bulat; Dragana Marković; Mirjana Gotić; Constance T Noguchi; Alan N Schechter; Radek C Skoda; Vladan P Čokić
Journal:  Mol Carcinog       Date:  2016-07-08       Impact factor: 4.784

10.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Authors:  M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-09-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.